Abstract
Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Current Cancer Therapy Reviews
Title: Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Volume: 3 Issue: 2
Author(s): Christopher B. Komanapalli, Charles R. Thomas and Mithran S. Sukumar
Affiliation:
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Abstract: Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Export Options
About this article
Cite this article as:
Komanapalli B. Christopher, Thomas R. Charles and Sukumar S. Mithran, Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618416
DOI https://dx.doi.org/10.2174/157339407780618416 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry Proteasomes as Drug Targets
Current Drug Targets Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Novel Hybrid Molecules of Isoxazole Chalcone Derivatives: Synthesis and Study of in vitro Cytotoxic Activities
Letters in Drug Design & Discovery RBM15 Functions in Blood Diseases
Current Cancer Drug Targets miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Lung Cancer Surgery in Patients with Chronic Obstructive Pulmonary Disease (COPD): Surgical Selection Challenges and Clinical Outcomes
Current Respiratory Medicine Reviews An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry In vitro activity and Cytotoxicity of Crocus sativus Extract against Leihmania Major (MRHO/IR/75/ER)
Infectious Disorders - Drug Targets Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals